The partnership pairs ABOC’s clinical expertise in implantology with Koite Health’s Lumoral, a CE-marked, light-activated antibacterial device used at home to reduce harmful oral biofilm. The research will look at how home-based antibacterial treatment fits into the full implant journey – from pre-treatment preparation through maintenance and long-term protection of periimplant tissue – and aims to build clinical evidence and preventive protocols that clinicians can use to support lasting implant outcomes.

“Long-term implant success depends as much on what happens between clinic visits as on the procedure itself, and prevention science in this space still has room to grow,” says Peter Rådqvist, CEO of Koite Health.

“Osseointegration was built on rigorous science and decades of long-term observation, and implant maintenance deserves the same level of attention as surgery,” says Robert Gottlander, CEO of ABOC.

Per-Olov Östman, professor at ABOC, said the network’s decades of patient follow-up show that healthy periimplant tissue is essential to preserving implant results, and that Lumoral “offers genuine clinical value as a simple, non-invasive home treatment” for biofilm control between visits – adding that ABOC’s early clinical experience with the device has been encouraging, particularly for tissue health and managing early signs of inflammation.